Abstract
The HSP90 molecular chaperone plays a key role in the maturation, stability and activation of its clients, including many oncogenic proteins. Kinases are a substantial and important subset of clients requiring the key cochaperone CDC37. We sought an improved understanding of protein kinase chaperoning by CDC37 in cancer cells. CDC37 overexpression in human colon cancer cells increased CDK4 protein levels, which was negated upon CDC37 knockdown. Overexpressing CDC37 increased CDK4 protein half-life and enhanced binding of HSP90 to CDK4, consistent with CDC37 promoting kinase loading onto chaperone complexes. Against expectation, expression of C-terminus-truncated CDC37 (ΔC-CDC37) that lacks HSP90 binding capacity did not affect kinase client expression or activity; moreover, as with wild-type CDC37 overexpression, it augmented CDK4-HSP90 complex formation. However, although truncation blocked binding to HSP90 in cells, ΔC-CDC37 also showed diminished client protein binding and was relatively unstable. CDC37 mutants with single and double point mutations at residues M164 and L205 showed greatly reduced binding to HSP90, but retained association with client kinases. Surprisingly, these mutants phenocopied wild-type CDC37 overexpression by increasing CDK4-HSP90 association and CDK4 protein levels in cells. Furthermore, expression of the mutants was sufficient to protect kinase clients CDK4, CDK6, CRAF and ERBB2 from depletion induced by silencing endogenous CDC37, indicating that CDC37’s client stabilising function cannot be inactivated by substantially reducing its direct interaction with HSP90. However, CDC37 could not compensate for loss of HSP90 function, showing that CDC37 and HSP90 have their own distinct and non-redundant roles in maintaining kinase clients. Our data substantiate the important function of CDC37 in chaperoning protein kinases. Furthermore, we demonstrate that CDC37 can stabilise kinase clients by a mechanism that is not dependent on a substantial direct interaction between CDC37 and HSP90, but nevertheless requires HSP90 activity. These results have significant implications for therapeutic targeting of CDC37.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Taipale M, Jarosz DF, Lindquist S . HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11: 515–528.
Pearl LH, Prodromou C, Workman P . The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008; 410: 439–453.
Gerber MR, Farrell A, Deshaies RJ, Herskowitz I, Morgan DO . Cdc37 is required for association of the protein kinase Cdc28 with G1 and mitotic cyclins. Proc Natl Acad Sci USA 1995; 92: 4651–4655.
Mandal AK, Lee P, Chen JA, Nillegoda N, Heller A, DiStasio S et al. Cdc37 has distinct roles in protein kinase quality control that protect nascent chains from degradation and promote posttranslational maturation. J Cell Biol 2007; 176: 319–328.
Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, Karras GI et al. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell 2012; 150: 987–1001.
Stepanova L, Leng X, Parker SB, Harper JW . Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996; 10: 1491–1502.
Grammatikakis N, Lin JH, Grammatikakis A, Tsichlis PN, Cochran BH . p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function. Mol Cell Biol 1999; 19: 1661–1672.
Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N . Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002; 277: 39858–39866.
Ghatak S, Misra S, Toole BP . Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 2005; 280: 8875–8883.
da Rocha DS, Friedlos F, Light Y, Springer C, Workman P, Marais R . Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005; 65: 10686–10691.
Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006; 103: 57–62.
Lavictoire SJ, Parolin DA, Klimowicz AC, Kelly JF, Lorimer IA . Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem 2003; 278: 5292–5299.
Siligardi G, Panaretou B, Meyer P, Singh S, Woolfson DN, Piper PW et al. Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. J Biol Chem 2002; 277: 20151–20159.
Roe SM, Ali MM, Meyer P, Vaughan CK, Panaretou B, Piper PW et al. The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 2004; 116: 87–98.
MacLean M, Picard D . Cdc37 goes beyond Hsp90 and kinases. Cell Stress Chaperones 2003; 8: 114–119.
Kimura Y, Rutherford SL, Miyata Y, Yahara I, Freeman BC, Yue L et al. Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev 1997; 11: 1775–1785.
Lee P, Rao J, Fliss A, Yang E, Garrett S, Caplan AJ . The Cdc37 protein kinase-binding domain is sufficient for protein kinase activity and cell viability. J Cell Biol 2002; 159: 1051–1059.
Turnbull EL, Martin IV, Fantes PA . Cdc37 maintains cellular viability in Schizosaccharomyces pombe independently of interactions with heat-shock protein 90. FEBS J 2005; 272: 4129–4140.
Rao J, Lee P, Benzeno S, Cardozo C, Albertus J, Robins DM et al. Functional interaction of human Cdc37 with the androgen receptor but not with the glucocorticoid receptor. J Biol Chem 2001; 276: 5814–5820.
Schwarze SR, Fu VX, Jarrard DF . Cdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival. Cancer Res 2003; 63: 4614–4619.
Pearl LH . Hsp90 and Cdc37—a chaperone cancer conspiracy. Curr Opin Genet Dev 2005; 15: 55–61.
Marino-Enriquez A, Ou WB, Cowley G, Luo B, Jonker AH, Mayeda M et al. Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene 2013, 10.1038/onc.2013.127. [Epub ahead of print].
Stepanova L, Finegold M, DeMayo F, Schmidt EV, Harper JW . The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. Mol Cell Biol 2000; 20: 4462–4473.
Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC et al. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 2000; 19: 2186–2193.
Smith JR, Clarke PA, de Billy E, Workman P . Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 2009; 28: 157–169.
Gray Jr. PJ, Stevenson MA, Calderwood SK . Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res 2007; 67: 11942–11950.
Gray Jr PJ, Prince T, Cheng J, Stevenson MA, Calderwood SK . Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer 2008; 8: 491–495.
Smith JR, Workman P . Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning. Cell Cycle 2009; 8: 362–372.
Shao J, Prince T, Hartson SD, Matts RL . Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37. J Biol Chem 2003; 278: 38117–38120.
Pratt WB, Toft DO . Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 2003; 228: 111–133.
Diehl JA, Zindy F, Sherr CJ . Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997; 11: 957–972.
Zhang W, Hirshberg M, McLaughlin SH, Lazar GA, Grossmann JG, Nielsen PR et al. Biochemical and structural studies of the interaction of Cdc37 with Hsp90. J Mol Biol 2004; 340: 891–907.
Terasawa K, Minami Y . A client-binding site of Cdc37. FEBS J 2005; 272: 4684–4690.
Katayama Y, Sakai A, Okikawa Y, Oue N, Asaoku H, Sasaki A et al. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells. Int J Oncol 2004; 25: 579–595.
Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA et al. Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology 2005; 42: 1310–1319.
Arlander SJ, Felts SJ, Wagner JM, Stensgard B, Toft DO, Karnitz LM . Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J Biol Chem 2006; 281: 2989–2998.
Farrell A, Morgan DO . Cdc37 promotes the stability of protein kinases Cdc28 and Cak1. Mol Cell Biol 2000; 20: 749–754.
Scholz G, Hartson SD, Cartledge K, Hall N, Shao J, Dunn AR et al. p50(Cdc37) can buffer the temperature-sensitive properties of a mutant of Hck. Mol Cell Biol 2000; 20: 6984–6995.
Sreeramulu S, Jonker HR, Langer T, Richter C, Lancaster CR, Schwalbe H . The human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopy. J Biol Chem 2009; 284: 3885–3896.
Jiang Y, Bernard D, Yu Y, Xie Y, Zhang T, Li Y et al. Split renilla luciferase protein-fragment-assisted complementation (SRL-PFAC) to characterize Hsp90/Cdc37 complex and identify critical residues in protein-protein interactions. J Biol Chem 2010; 285: 21023–21036.
Vaughan CK, Gohlke U, Sobott F, Good VM, Ali MM, Prodromou C et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell 2006; 23: 697–707.
Karnitz LM, Felts SJ . Cdc37 regulation of the kinome: when to hold 'em and when to fold 'em. Sci STKE 2007; 2007: e22.
Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D . Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem 2009; 284: 35381–35389.
Yu Y, Hamza A, Zhang T, Gu M, Zou P, Newman B et al. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 2010; 79: 542–551.
Salminen A, Lehtonen M, Paimela T, Kaarniranta K . Celastrol: Molecular targets of Thunder God Vine. Biochem Biophys Res Commun 2010; 394: 439–442.
Polier S, Samant RS, Clarke PA, Workman P, Prodromou C, Pearl LH . ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol 2013; 9: 307–312.
Shao J, Irwin A, Hartson SD, Matts RL . Functional dissection of cdc37: characterization of domain structure and amino acid residues critical for protein kinase binding. Biochemistry 2003; 42: 12577–12588.
Vaughan CK, Mollapour M, Smith JR, Truman A, Hu B, Good VM et al. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol Cell 2008; 31: 886–895.
Miyata Y, Nishida E . Supervision of multiple signaling protein kinases by the CK2-Cdc37 couple, a possible novel cancer therapeutic target. Ann N Y Acad Sci 2004; 1030: 150–157.
Hobbs S, Jitrapakdee S, Wallace JC . Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 1998; 252: 368–372.
Acknowledgements
We thank our colleagues in the Signal Transduction and Molecular Pharmacology Team and Chaperone Project Team for helpful discussions and Craig McAndrew for valuable assistance with gel filtration. The authors’ work is supported by Cancer Research UK Programme grant number C309/A8274 and C309/A11566. PW is a Cancer Research UK Life Fellow.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
PW has received research funding on HSP90 inhibitors from Vernalis, and intellectual property from this collaboration has been licensed to Vernalis and Novartis. PW has been a consultant to Novartis.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Smith, J., de Billy, E., Hobbs, S. et al. Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins. Oncogene 34, 15–26 (2015). https://doi.org/10.1038/onc.2013.519
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.519
Keywords
This article is cited by
-
Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma
Nature Reviews Urology (2022)
-
Adapting to stress — chaperome networks in cancer
Nature Reviews Cancer (2018)
-
The co-chaperone Cdc37 regulates the rabies virus phosphoprotein stability by targeting to Hsp90AA1 machinery
Scientific Reports (2016)
-
Hyperthermia enhances 17-DMAG efficacy in hepatocellular carcinoma cells with aggravated DNA damage and impaired G2/M transition
Scientific Reports (2016)
-
The epichaperome is an integrated chaperome network that facilitates tumour survival
Nature (2016)